Covid-19: MedinCell presents positive first results from the clinical trial aiming at validating the safety of continuous administration of Ivermectin
17 December 2020
FOR ANY FURTHER INFORMATION,
PLEASE CONTACT:
communication@medincell.com
Our news
Bringing you the latest!
All news
MedinCell publishes its first-half 2020/2021 financial results (April – September 2020): operating expenses and portfolio development in line with expectations
9 December 2020
First long-acting injectable (LAI) antipsychotic using MedinCell’s technology reaches Phase 3 clinical study primary completion date
12 November 2020
MedinCell initiates the first clinical trial of its Covid-19 prevention program
29 September 2020
MedinCell releases the results of its September 10, 2020 ordinary annual and extraordinary general meeting
11 September 2020
Adapt and overcome in response to the Covid-19 crisis
23 April 2020
MedinCell launches Regulatory Development of mdc-WWM Program
22 April 2020
Invitation to a webcast: adapting and acting in response to the Covid-19 crisis
20 April 2020
Press
Communication leader
MedinCell
David Heuzé
david.heuze@medincell.com
+33 (0)6 83 25 21 86
Media
NewCap
Nicolas Merigeau
medincell@newcap.eu
+33 (0)1 44 71 94 94
Investors
Investor Relations
NewCap
Louis-Victor Delouvrier /
Alexia Faure
medincell@newcap.eu
+33 (0)1 44 71 94 94